Palmitoylethanolamide (PEA) (544-31-0) Mea hana - Cofttek

Palmitoylethanolamide (PEA) (544-31-0)

April 7, 2020

ʻO Palmitoylethanolamide (PEA), kahi endogenous (hana ʻia e ke kino) fatty acid amide, ke kū nei kahi mea hou i ka mālama ʻana i ka ʻeha a me ka mumū. Kēia mea endogenous a me kekahi i loaʻa i loko o nā meaʻai e like me ka hua a me ka waiū, ʻaʻohe hopena koʻikoʻi a i ʻole lāʻau lapaʻau-lāʻau lapaʻau i ʻike ʻia.


Kūlana: I ka Production Production
Mokuna: 25kg / Drum

Palmitoylethanolamide (PEA) (544-31-0) wikiō

Palmitoylethanolamide (PEA) Snāʻike

Name: Palmitoylethanolamide (PEA)
CAS: 544-31-0
Purity 98% loea Micronized PEA ; 98% pauna
Nā Kaulike Molecular: C18H37NO2
Molecular Weight: 299.49 g / mole
Wahi Manaʻo: 93 a 98 ° C
Inoa inoa inoa inoa: Palapala Lehua Hydrxyethylpalmitamide Palmidrol N-Palmitoylethanolamine Palmitylethanolamide
Hōʻuluʻulu Manaʻo: Palmitoylethanolamide

ʻO Palmidrol

N- (2-Hydroxyethyl) hexadecanamide

N-palmitoylethanolamine

InChI Key: HXYVTAGFYLMHSO-UHFFFAOYSA-N
Half Ola: 8 hola
Palekana: Hoʻopau maikaʻiʻia i DMSO, Methanol, Wai
Ke kūlana Mana: 0 - 4 C no kekahi manawa pōkole (mau lā i nā wiki), a -20 C no ka wā lōʻihi (mau mahina)
noi: ʻO Palmitoylethanolamide (PEA) noho i ka ʻohana endocannabinoid, he hui o nā momona amides fatty. Ua hōʻike ʻia ʻo PEA i ka hana analgesic a me nā hana anti-inflammatory a ua hoʻohana ʻia i loko o nā hana i hoʻopaʻa ʻia i hoʻomohala ʻia i ka hoʻokele o ka ʻeha ʻo ka maʻi ma waena o nā poʻe maʻi me nā ʻano kumu loiloi i lalo.
ʻAno: ʻO ka pauma

He aha ka Palmitoylethanolamide (544-31-0)?

ʻO Palmitoylethanolamide (PEA), kahi endogenous (hana ʻia e ke kino) fatty acid amide, ke kū nei kahi mea hou i ka mālama ʻana i ka ʻeha a me ka mumū. E like me ka mea hoʻopiha endogenous a loaʻa pū kekahi i nā meaʻai e like me ka hua a me ka waiū, ʻaʻohe hopena koʻikoʻi a me nā hopena lāʻau lapaʻau-ʻike ʻia. Ua hōʻike ʻo PEA i ka hana pono no ka ʻeha ʻo ke ʻano o nā ʻano like ʻole e pili ana i nā maʻi hōʻeha, a me ka hōʻeha ʻana me ka maʻi neuropathic (nerve), ka ʻeha a me nā ʻeha visceral e like me ka endometriosis a me interstitial cystitis.

Loaʻa iā Palmitoylethanolamide (544-31-0)

I ka manawa mua, hoʻemi ʻia, ma o ka peroxisome proliferator-activated receptor alpha (PPARα), ka hoʻoulu ʻia a me ka hoʻihoʻi ʻana i nā cell mast i nā wahi o ka hōʻeha kino a me ka hoʻokuʻu ʻana i nā mea hoʻopuka pro-inflammatory mai kēia mau loko; lua ka mea, ke pale aku nei i ka hoʻōla ʻana o ka microglia a me ka loaʻa ʻana o nā huelo mast i loko o ka pūpū ma hope o ka hōʻeha ʻana o ka iwi ma hope, a me ka ʻimi ʻana i ka ʻākuʻi neuroinflamulea a me ka hōʻeha manamana lima.

Ua paʻa kekahi mau noiʻi i ka hoʻohana ʻana o PEA i ka nui o nā kūlana ʻeha kuʻuna. No ka laʻana, hiki iā ia ke loaʻa he hopena maikaʻi e like me ka adjuvant no ka mālamaʻana i ka ʻeha o ka ʻeha hope a i hoʻohana wale ia no ka mālama ʻeha ʻana i nā maʻi maʻi maʻi ʻoihana, ma kahi o ka hoʻohana ʻana i nā analgesics kuʻuna e hiki ke alakaʻi i ka hopena kiʻekiʻe. Hōʻike ʻia nā hualoaʻa ma ka mālama ʻana i nā radiculopathies non-surgical me kahi hoʻolālā ultra-micronized o PEA a me ka hui pū ʻana me ka waika alpha-lipoic e hōʻemi i ka maʻi prostatitis / maʻi pelvic maʻi syndrome.

Palmitoylethanolamide (544-31-0) Hoʻolaha i ka hana?

ʻO Palmitoylethanolamide (PEA) he amine fatty endogenous fatty acid, kahi analog o ka endocannabinoid anandamide (AEA), nona nā ʻohana N-acylethanolamines (NAE). Hoʻokuʻu ʻia nā NAE mai nā cell i pane i ka hoʻoulu ʻana noxious. E like me nā mea āpau o NAE, he hopena nō hoʻi ka PEA, a pili pono ka paʻila o kona kiko ma o ke kaila o ka hana a me ka hana i hōʻino ʻia. Ua komo kahi ʻelua intracellular amidases, i hōʻike ʻia i loko o nā ʻili maʻi, i ka hoʻoneʻe ʻana o lipid amide: ka fatty acid acid-acid amidase (FAAH) a me N-acylethanolamine hydrolyzing acid amidase (NAAA).

Palmitoylethanolamide (544-31-0) noi

ʻO Palmitoylethanolamide (PEA) noho i ka ʻohana endocannabinoid, he hui o nā momona amides fatty. Ua hōʻike ʻia ʻo PEA i ka hana analgesic a me nā hana anti-inflammatory a ua hoʻohana ʻia i loko o nā hana i hoʻopaʻa ʻia i hoʻomohala ʻia i ka hoʻokele o ka ʻeha ʻo ka maʻi ma waena o nā poʻe maʻi me nā ʻano kumu loiloi i lalo.

Palmitoylethanolamide (PEA) ka lehu no ka kuai(Ma ke kūʻai aku i ka pulupulu Palmitoylethanolamide (PEA) pauka)

ʻOliʻoli kā mākou ʻoihana i nā pilina lōʻihi e ko mākou mea kūʻai aku no ka mea ke nānā aku nei mākou i ka lawelawe o ka mea kūʻai aku a hāʻawi i nā huahana maikaʻi. Inā makemake ʻoe i kā mākou huahana, maʻalahi mākou me ka hoʻokaʻawale ʻana i nā kauoha e kūpono i kāu pono kūikawā a me ko mākou wikiwiki wikiwiki i nā kauoha e hōʻoia ʻoe e hoʻāʻo nui i kā mākou huahana i ka manawa. Hoʻomaopopo pū mākou i nā lawelawe i hoʻohui ʻia. Loaʻa mākou i nā nīnau a me ka ʻike e kākoʻo i kāu ʻoihana.

ʻO mākou kahi mea ʻenehana palmitoylethanolamide (PEA) loea no nā makahiki he nui, hoʻolako mākou i nā huahana me ke kumukūʻai kūʻai, a ʻo kā mākou huahana he mea kiʻekiʻe loa a hoʻokuʻi i ka hoʻāʻo kūʻokoʻa, kūʻokoʻa ʻole e hōʻoia ka palekana i ka hoʻohana ʻana i ka honua a puni.

E hoʻomaopopo '

  • Hansen HS. ʻO Palmitoylethanolamide a me nā mea hou o ka anandamide. Hoʻolālā ʻia i ka lolo maʻi maʻi. Exp Neurol. 2010; 224 (1): 48-55
  • Petrosino S, Iuvone T, Di Marzo V. N-palmitoyl-ethanolamine: biochemistry a me nā manawa kūpono hou i ka therapeutic. Biochimie. 2010; 92 (6): 724–7
  • Cerrato S, Brazis P, della Valle MF, Miolo A, Puigdemont A. Nā hopena o ka palmitoylethanolamide ma ka histamine immunologically induced, PGD2 a me TNFα i hoʻokuʻu mai i nā ʻila a me ka hoʻoluʻu manu canine. ʻO Vet Immunol Immunopathol. 2010; 133 (1): 9–15
  • Palmitoylethanolamide (PEA): pōmaikaʻi, Dosage, Hoʻohana, hoʻohui